Novel therapeutic agents in Waldenstrom's macroglobulinemia.

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenstrom’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.